Skip to main content
. Author manuscript; available in PMC: 2015 Jul 28.
Published in final edited form as: J Cancer Ther. 2011 Mar 31;2(1):22–39. doi: 10.4236/jct.2011.21004

Figure 5.

Figure 5

Relative anti-neoplastic potency of covalent epirubicin-(C13-imino) and epirubicin-(C3-amide) immunochemotherapeutics against chemotherapeutic-resistant SKBr-3 mammary carcinoma. Legend: (◆) covalent epirubicin-(C13-imino)-[anti-HER2/neu] epirubicin immunochemo-therapeutic, and (∎) covalent epirubicin-(C3-amide)-[anti-HER2/neu] with epirubicin-(C3-amide)-[anti-EGFR] formulated as a 50/50 immunochemotherapeutic combination. Previous investigations revealed that a 50/50 immunochemotherapeutic combination of covalent epirubicin-(C3-amide)-[anti-HER2/neu] with epirubicin-(C3-amide)-[anti-EGFR] was more potent than either covalent epirubicin-(C3-amide) immunochemotherapeutic alone [10]. Monolayers of SKBr-3 mammary carcinoma were incubated with covalent epirubicin-immunochemotherapeutic for 72-hours and cytotoxicity measured as a function of MTT cell vitality relative to matched negative reference controls.